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Abstract: Biallelic mutations in the NBS1 gene are responsible for the Nijmegen breakage syndrome (NBS), a rare auto-
somal recessive disorder characterized by chromosome instability and hypersensitivity to ionising radiation (IR). Epide-
miological data evidence that the NBS1 gene can be considered a susceptibility factor for cancer development, as demon-
strated by the fact that almost 40% of NBS patients have developed a malignancy before the age of 21. Interestingly, also 
NBS1 heterozygotes, which are clinically asymptomatic, display an elevated risk to develop some types of malignant tu-
mours, especially breast, prostate and colorectal cancers, lymphoblastic leukaemia, and non-Hodgkin’s lymphoma (NHL). 
So far, nine mutations in the NBS1 gene have been found, at the heterozygous state, in cancer patients. Among them, the 
657del5, the I171V and the R215W mutations are the most frequently described. The pathogenicity of these mutations is 
presumably connected with their occurrence in the highly conserved BRCT tandem domains of the NBS1 protein, which 
are present in a large superfamily of proteins, and are recognized as major mediators of processes related to cell-cycle 
checkpoint and DNA repair.  
This review will focus on the current state-of-knowledge regarding the correlation between carriers of NBS1 gene muta-
tions and the proneness to the development of malignant tumours. 
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INTRODUCTION 
  Mutations at the homozygous status in the NBS1 gene 
(known also as NBN) are responsible for a rare disease 
known as Nijmegen breakage syndrome (NBS; OMIM 
251260), an autosomic recessive disorder whose signs are a 
distinct facial appearance, microcephaly, immunodeficiency, 
chromosome rearrangements and sensitivity to ionising ra-
diation [1]. In NBS, a defective response to face DNA dam-
age is associated with chromosomal instability, and in turn 
with a strong predisposition to develop malignancy, in par-
ticular lymphomas [2, 3]. The majority of them are non 
Hodgkin’s lymphoma (NHL) (with a high incidence of dif-
fuse large B-cell lymphomas), lymphoblatic anaemia, and 
Hodgkin lymphoma (HL). Among solid tumours, medul-
loblastoma has been observed in four patients [4], and rhab-
domiosarcoma of the perianal region in three others [5]. 
Since the latter is extremely uncommon among children, a 
strong association with NBS has been suggested [5]. All the 
11 disease-causing mutations so far identified in NBS1 gene 
have been found within exons 6-10 (Fig. 1), and 8 of them 
result in premature truncation of the NBS1 protein, with the 
possible synthesis of NBS1 variants of lower molecular 
weight [6]. 
  As a measure of cancer incidence in NBS, the Polish reg-
istry report that 40% of patients suffering for NBS developed  
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lymphoma within the first two decades of life [3]. Though 
NBS is a recessive disease and one would not expect any 
cellular feature or clinical symptom, a growing number of 
papers report higher spontaneous and induced chromosome 
instability and an increased incidence of tumours among 
NBS carriers. The FISH chromosome painting analysis re-
vealed that NBS carriers display a 3-fold higher rate of chro-
mosome translocations compared with non-carriers [7]. 
Furthermore, the same authors reported that after irradiation, 
the response of cells from heterozygous carriers was inter-
mediate between that of NBS homozygous and normal indi-
viduals, and could be clearly differentiated from those of the 
other groups in double-coded studies. Moreover, NBS het-
erozygosity can be distinguished from other genotypes by 
the number of the long-lived stable aberrations in NBS cells 
[8]. Radiation hypersensitivity in NBS carriers seems any-
how restricted to cells irradiated in the G1-phase, whereas the 
number of chromatid-aberrations scored in G2-phase-treated 
NBS heterozygous cells is in the range of normal cells or 
slightly higher [9].  
  Nine mutations localized in the coding sequence of the 
NBS1 gene have been found, at the heterozygous state, in 
cancer patients (Fig. 1). The 657del5 (or founder mutation), 
the 511A>G (I171V), the 643C>T (R215W), and the 
742insGG mutations were found both in NBS patients and in 
cancer patients. Four mutations have been found in cancer 
patients only (278C>T, 381C>T, 448G>T, and 628G>T). 
The 283G>A (D95N) mutation, has been identified both in 
cancer patients and in healthy controls [10], but is not listed 
as known NBS1 polymorphism by the NCBI website [11].  276    Current Genomics, 2008, Vol. 9, No. 4  di Masi and Antoccia 
NBS1 MUTATIONS AND CANCER RISK 
  The first evidence of a possible correlation between 
NBS1 carriers and cancer risk, came from family data stud-
ies, indicating that blood relatives of NBS patients with the 
657del5 founder mutation had a high probability to develop 
malignancy [12]. From 1998, several studies have exami-
nated the frequency of the NBS1  mutations in cancer pa-
tients. In Table 1, we have collected all the existing data rela-
tive to the frequency of cancer in heterozygotes for the 
commonest NBS1 gene mutations, in particular the 657del5, 
the R125W, the I171V, and the IVS11+2insT mutations. The 
relative distribution of these mutations in NBS1 heterozy-
gous cancer patients is illustrated in Fig. (2).  
The 657del5 Mutation  
  The 657del5 hypomorphic germ line mutation in exon 6 
of  NBS1 gene, accounts for more than 90% of all mutant 
alleles in NBS. The highest frequency of heterozygous carri-
ers of the 657del5 mutation has been found in the Slavic 
population of Central Europe, with an average frequency of 
1/177 [13]. A total number of 81 carriers of 7474 cancer pa-
tients (1.8%), have been so far identified (Table 1). 
    The evidence of a strong correlation between 657del5 
mutation heterozygous carriers and cancer risk, has been 
strengthened by a large study on 344 blood relatives (first- 
through fourth-degree) of NBS patients, in 24 different NBS 
families of Czech Republic and Slovakia, from 1998 to 2003 
[14]. Thirteen blood relatives developed malignancies of any 
type, among them eleven were carriers of the 657del5 NBS1 
mutation, compared with 6 expected. In this study, the most 
frequently type of cancer observed was stomach and colorec-
tal cancer. Breast cancers were also reported, though at a 
lower frequency [14].  
  The cancer risk of the 657del5 mutation carriers has been 
also assessed in cancer patients with no NBS cases in the 
family. It was found that carriers of the 657del5 mutation 
were about twice more frequent among cancer patients than 
among matched controls [15]. Most of the 657del5 carriers 
were found among patients with melanoma (3.8%; OR: 
6.376, p=0.0081), NHL (4.8%; OR: 8.05, p=0.0351), breast 
cancer (1.8%; OR: 2.927, p=0.0795), and colorectal cancer 
(1.3%; OR: 2.091, p=0.2197) [15]. Moreover, malignant 
tumours among parents and siblings of 657del5 carriers were 
twice more frequent (14/77) than in population control [15]. 
Interestingly, in a study on 2.400 healthy NBS1 heterozygous 
Polish women, emerged a frequency of 96/10.603 (8.8%) 
malignant tumours among parents and siblings. This sug-
gested that first-degree relatives of the 657del5 mutation 
carriers may have an elevated risk of cancer [15]. Heterozy-
gotes for the 657del5 mutation are about three times more 
frequent among non-selected breast cancer patients than ex-
pected. Since an elevated risk of breast cancer has been also 
observed among carriers of mutations in the BRCA1, p53 and 
ATM genes [16, 17], and because these gene products inter-
act with each other and with NBS1 [18], these findings sug-
gest that NBS1 is another gene that might be associated with 
increased risk of breast cancer in heterozygotes [15].  
The R215W Mutation  
  The R215W mutation has been considered for a long 
time a polymorphism of NBS1, and only recently its severe 
pathogenicity is emerged with the identification of com-
pound heterozygous 657del5/R215W NBS patients [19].  
  The R215W missense mutation was first described in a 
case of acute lymphoblastic leukemia (ALL) and in 9 
probands of Slavic origin from a population-based study 
[10]. Subsequently, a high frequency of heterozygous carri-
ers of the R215W mutation was found not only among chil-
dren affected by ALL (2.1%), but also by HL (2.6%) (Table 
1) [20]. 
   The R215W mutation has been also detected among sev-
eral cancer patients, complexively in 34 of 4251 individuals 
with tumours (0.85%) (Table 1). Several studies conducted 
among Poland, Germany, Czech Republic and United King-
dom, report that heterozygous carriers of the R215W mis-
sense mutation have an increased risk of colorectal cancer 
(1.3%), prostate cancer (1.6%), NHL (1.07%), and breast 
cancer (0.6%) (Table 1) [15, 21-24].  
The I171V Mutation  
  The 511A>G (I171V) germ-line mutation was identified 
for the first time in 5 of 47 children with ALL [10]. These 
children were all characterized by late prognoses due to a 
late relapses [10]. The same mutation, at the homozygous 
state, was detected in a Japanese patient with aplastic anae-







Fig. (1). Coding sequence variants of NBS1 gene identified to date (modified from http://www.nijmegenbreakagesyndrome.net). Grey: high 
frequency polymorphisms; grey*: low frequency polymorphisms; black: mutations found in NBS patients; black*: mutations also found in 
cancer patients at the heterozygous state; black: mutations found in cancer patients only; grey: mutation found both in cancer patients and in 
healthy controls. NBS1 Heterozygosity and Cancer Risk  Current Genomics, 2008, Vol. 9, No. 4    277 
Table 1.  Frequency of the 657del5, R215W, I171V, and IVS11+2insT NBS1 Gene Mutations-Type Among NBS1 Heterozygotes 
Tumour and Control Subjects (NHL: Non-Hodgkin Lymphoma; ALL: Acute Lymphoblastic Leukaemia; HL: Hodgkin 
Lymphoma). (nad: Not Available Data) 
NBS1 Mutation  Patient Age  Cancer Type 
N° of NBS1 Mutation  
Carriers Among  
Tumour Patients 
N° of NBS1 Mutation  





colorectal  3/234 (1.3%)  10/1620 (0.6%)  OR: 2.091, p=0.2197  [15] 
breast  4/224 (1.8%)  10/1620 (0.6%)  OR: 2.927, p=0.0795  [15] 
  11/562 (1.96%)  nad  OR: 3.21, p = 0.0107  [48] 
  1/477 (0.2%)  1/866 (0.1%)  OR: 1.8, p=0.76  [49] 
  7/873 (0.8%)  2/692 (0.3%)  OR: 2.8, p=0.32  [50] 
  2/2012 (0.8%)  18/4000 (0.5%)  OR: 1.9, p=0.09  [51] 
  2/150 (1.3%)  3/530 (0.56%)  
2 test, p<0.0001  [51] 
  3/80 (3.75%)  3/530 (0.56%)  
2 test, p<0.0001  [51] 
melanoma  4/105 (3.8%)  10/1620 (0.6%)  OR: 6.376, p=0.0081  [15] 
 1/376  (0.26%)  0  nad  [23] 
NHL  2/42 (4.8%)  10/1620 (0.6%)  OR: 8.05, p=0.0351  [15] 
  8/228 (3.5%)  10/1620 (0.6%)  OR: 5.85, p=0.0001  [22] 
prostate  5/56 (9%) (familial)  9/1500 (0.6%)  OR: 16, p>0.0001   [52] 
  7/305 (2.2%)(non familial)  9/1500 (0.6%)  OR: 3.9, p=0.01  [52] 
adult 
gastrointestinal lymphoma  4/37 (10.8%)  10/1620 (0.6%)  OR: 19.52, p=0.0002  [22] 
NHL  1/68 (1.5%)  11/2261 (0.49%)  
2 test, p<0.0001  [53] 
  2/212 (0.9%)  42/6984 (0.6%)  OR: 1.57, p=0.041  [54] 
ALL  3/270 (1.1%)  42/6984 (0.6%)  OR: 1.85, p=0.035  [54] 
  1/68 (1.5%)  11/2261 (0.49%)  
2 test, p<0.0001  [53] 
ALL+NHL+HL  5/545 (0.9%)  42/6984 (0.6%)  OR: 1.48, p=0.037  [54] 
ALL+NHL  5/482 (1.03%)  42/6984 (0.6%)  OR: 1.73, p=0.029  [54] 
657del5 
children 
 2/68  (2.9%)  0 nad  [55] 
colorectal  3/234 (1.3%)  4/1620 (0.2%)  OR: 5.247, p=0.0472  [15] 
breast  9/1588 (0.6%)  5/1014 (0.5%)  OR: 1.9, p=0.18  [24] 
  9/1076 (0.8%)  2/1017 (0.2%)  OR: 1.9, p=0.18  [24] 
melanoma  1/376 (0.26%)   nad  nad  [23] 
NHL  2/186 (1.07%)   10/1620 (0.6%)  nad  [22] 
prostate  6/338 (1,78%) (sporadic)   3/208 (1.4%)  OR: 1.24, p =0.77  [21] 
adult  
  2/139 (1,44%) (non familial)  3/208 (1.4%)  OR: 1, p=1  [21] 
HL 1/39  (2.6%)  nad  nad  [20] 
R215W 
children 
ALL  1/47 (2.1%)   nad  nad  [10] 
larynx cancer  4/176 (2.3%)   1/500 (0.2%)  OR: 11.7, p=0.0175  [26] 
multiple primary tumors  5/93 (5.4%)   1/500 (0.2%)  OR: 28.35, p=0.0005  [26] 
breast  20/1636 (1.2%)   18/1014 (1.8%)  OR: 0.68, p=0.3  [24] 
  10/1048 (0.9%)  7/1017 (0.7%)  OR: 1.39, p=0.7  [24] 
  5/270 (1.8%)   1/500 (0.2%)  OR: 9.42, p=0.02  [27] 
head and neck  5/81 (6.17%)   1/600 (0.17%)  OR: 39.41, p=0.0001  [28] 
I171V adult 
colorectal carcinoma  3/131(2.29%)   1/600 (0.17%)  OR: 14.39, p=0,0196  [28] 
lung  2/532 (0.4%)  2/2348 (0.08%)  OR: 4.43, p=0.16  [29] 
gastric cancer  2/472 (0.4%)  2/2348 (0.08%)  OR: 25, p<0.0001  [29]  IVS11+2insT adult 
colorectal cancer  3/472 (0.6%)  2/2348 (0.08%)  OR: 9.43, p=0.02  [29] 













Fig. (2). Distribution of the 657del5, R215W, I171V, and IVS11+ 
2insT NBS1 gene mutations-type among NBS1 heterozygotes af-
fected with tumour. 
study aimed to assess the frequency of NBS1 mutations in 
patients with larynx cancer and multiple primary tumours, is 
emerged that the frequency of the I171V mutation carriers is 
significantly higher than in population controls (2.3% in lar-
ynx cancer patients, p=0.0175; 5.4% in multiple primary 
tumours, p=0.0005). These results imply that the I171V mu-
tation contributes significantly to the overall incidence of 
larynx carcinoma [26]. 
  An investigation in the Polish population has provided 
evidences that the I171V mutation could be associated with 
an increased breast cancer risk (1.8% of I171V carriers, 
p=0.02) [27]. In particular, this association concerns patients 
with breast cancer, whose first-degree relatives also had di-
agnosis of those malignancies [27]. However, in an associa-
tion study in two large hospital-based case-control settings 
from Germany and Belarus, is emerged that the I171V mis-
sense mutation does not significantly increase the breast can-
cer risk (0.9% of I171V carriers, p=0.7) [24].  
  Very recently, it has been shown that the 2.58% of stud-
ied patients with malignancies are carriers of the I171V mu-
tation, compared to the 0.17% in the control group (p=0.00 
02). The percentage of the mutation carriers is particularly 
high among patients with neck and head tumours (6.17%, 
p=0.0001), thus suggesting that the I171V mutation in NBS1 
gene may be susceptibility factor in solid tumours [28].  
The IVS11+2insT Mutation 
  The IVS11+2insT mutation has been described for the 
first time in heterozygous Japanese subjects [29], with an 
increased risk of gastrointestinal cancer that originate in the 
stomach (2% of carriers, p<0.0001), and in the colorectum 
(0.8% of carriers, p=0.02) [29]. Interestingly, even if there is 
not a statistical significant correlation between carriers of the 
IVS11+2insT mutation and development of lung cancer, it is 
noteworthy that patients with this type of tumour and het-
erozygous for the IVS11+2insT mutation, are characterized 
by a relatively early onset [29]. Since it has been suggested 
the existence of a mendelian inheritance in the pathogenesis 
of lung cancer [30, 31], it has been proposed the possibility 
that the rare autosomal gene contributing to the early onset 
of lung cancer may be NBS1 [29].  
  The IVS11+2insT mutation represent the first reported 
example of a germ line mutation that strongly predisposes to 
gastric cancer development in the Japanese population. Tak-
ing into account that each year 100.000 new case of gastric 
cancer arises in Japan [32], it is possible to hypothesize that 
heterozygous carriers of the IVS11+2insT mutation are sus-
ceptible to the development of gastric and colon carcinomas 
[29].  
BIOCHEMICAL EFFECTS OF THE NBS1  MUTA-
TION ON THE STRUCTURE AND FUNCTION OF 
THE NBS1 PROTEIN 
  The NBS1 protein is part of a nuclear multi-protein com-
plex composed also by MRE11 and RAD50 (MRN com-
plex), which plays a crucial role in the response to DNA 
double strand breaks (DSBs), a lesion generated by both en-
dogenous factors and environmental agents as ionising radia-
tions [33, 34]. NBS1 consists of 754 amino acids, has a mo-
lecular weight of 95kDa, and is composed by three regions: 
the N-terminus, the central region, and the C-terminus (Fig. 
3A). The N-terminal region contains a fork-head associated 
(FHA) domain (amino acids 24-109) and two breast cancer 
C-terminus (BRCT) domain (BRCT1: amino acids 114-183; 
BRCT2: amino acids 221-291) [35-37]. The central region 
contains several consensus sequences for phosphorylation by 
ATM or ATR kinases [38-40]. The C-terminal region (amino 
acids 665-693) contains a MRE11 binding domain [41], and 
an ATM recruitment motif [42].  
  Low expression of abbreviated polypeptides of both N-
terminal and C-terminal NBS1 has been demonstrated in 
NBS lymphoblastoid cell lines with different mutations. Par-
ticularly, C-terminal peptides of lower molecular weight than 
95kDa, which maintain the ability to interact with MRE11, 
has been detected by means of a co-immunoprecipitation 
assay in lymphoblastoid NBS cell lines [6, 9]. NBS cells 
characterised by the presence of the classical mutation 
657del5 in the NBS1 gene, show two alternative forms of 
NBS1 with a lower molecular weight, of approximately 26 
and 70 kDa. In particular, the 5bp deletion in position 657 
splits the BRCT tandem domain exactly in the linker region 
that connects the two BRCT domains. The 26kDa protein 
includes the region 1-218 of the NBS1 protein, and com-
prises the FHA and the first BRCT domains. The 70kDa 
protein is produced by an alternative initiation of translation 
upstream the 5bp deletion: after a 18 residue extension at the 
N-terminus, the sequence is identical to that of the wild type 
NBS1, from the amino acid 221 to the end, and contains the 
second BRCT domain and the C-terminal half of NBS1 
[37,43] (Fig. 3B).  
  The R215W missense mutation determines the substitu-
tion at position 215 of an arginine (R) with a tryptophan (W). 
The 215 residue of NBS1 protein is located at the C-terminus 
of the BRCT1 domain, right before the linker region which 
connects the two BRCT domains, and seems to be pivotal for 
the relative orientation of the NBS1 BRCT domains [44] 
(Fig. 3C). Since tryptophan is a hydrophobic and bulky resi-
due, it could lead to a perturbation of the relative geometry 
of the tandem BRCT domains. It has been demonstrated, in 
fact, that the R215W mutation in NBS1 impairs histone -
H2AX binding after induction of DNA damage, leading to a 
delay in DNA-DSB rejoining [44].  NBS1 Heterozygosity and Cancer Risk  Current Genomics, 2008, Vol. 9, No. 4    279 
  The pathogenic character of the I171V mutation is pre-
sumably connected with its occurrence in the BRCT1 do-
main of NBS1 (Fig. 3D). So, similarly to the R215W muta-
tion, the I171V may perturb the proper geometry of the tan-
dem BRCT domain, thus impairing the binding to -H2AX 
and the delocalization of the MRN complex to the vicinity of 
the DNA damage site [26,45]. 
  The IVS11+2insT mutation determines the lacking of the 
MRE11- and ATM-binding domain at the C-terminus of the 
NBS1 protein [29] (Fig. 3E). This determines the synthesis 
of an 80kDa protein, defective in the interaction with 
MRE11, MDC1, BRCA1 and ATM [29]. 
CONCLUSIONS 
  Epidemiological data so far collected point to an in-
creased risk of cancer incidence in heterozygous carriers of 
the 657del5, R215W, I171V, and IVS11+2insT mutations of 
the NBS1 gene. 
  The only NBS1 657del5 founder mutation frequency 
among newborns is 1:154 in Czech Republic, 1:182 in 
Ukraine (Lvov region), 1:190 in Poland, with a mean preva-
lence of 1:177 for the three populations tested [13], whereas 
the NBS1 R215W mutation frequency among Czech new-
borns is 1:234 [46]. A moderately elevated risk in heterozy-
gous carriers would results in hundreds of new cancer cases 
in these populations every year. Because it cannot be ex-
cluded that cancer patients who carry germ-line NBS1 muta-
tions may show a specific sensitivity to treatment with ionis-
ing radiation or cytostatic drugs, as recently shown [8], sys-
tematic studies are now under way to protocol their re-
sponses to radio- and chemotherapy. 
 Experimental  support  that  NBS1  heterozygosity predis-
pose cells to malignancy, come from a study in which the 
mouse homologue of the human NBS1 gene, Nbn, was dis-
rupted in mice [47]. Nbn
+/- mice showed a significantly in-
creased occurrence of spontaneous solid tumours (epithelial 
tumours affecting the liver, prostate and mammary glands, 
and gonad malignancy) in addition to lymphoma. Moreover, 
ionising radiation dramatically increased cancer formation in 
Nbn
+/- mice, especially thyroid tumours. These data provide 
a clear relationship between NBS1 heterozygosity, radiation 
sensitivity and increased cancer risk. Interestingly, examina-


















Fig. (3). Wild type and mutated NBS1 proteins. (A) Structure of the NBS1 wild-type protein. (B) The 657del5 mutation, which splits up the 
tandem BRCT domains, determines the expression of two truncated proteins of 26 and 70kDa. (C) The R215W mutation occurs in the linker 
region that connects the two BRCT domains, and determines the substitution at position 215 of an arginine (R) with a tryptophan (W). (D) 
The I171V missense mutation occurs in the first BRCT domain, and determines the substitution at position 171 of an isoleucine (I) with a 
valine (V). (E) The NBS1 protein arising from the IVS11+2insT mutation, is characterised by the absence of the MRE11- and ATM-binding 
domain at the C-terminus. (MBD: MRE11 binding domain; ABD: ATM binding domain). 280    Current Genomics, 2008, Vol. 9, No. 4  di Masi and Antoccia 
the wild-type allele, suggesting that haploinsufficiency is the 
presumed pathogenic mechanism. In contrast, for human 
heterozygotes, the possible existence of a truncated protein 
produced by alternative translation [6], and capable of inter-
action with MRE11 would be compatible with a dominant 
negative mechanism. 
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ABBREVIATIONS 
NBS1  =  Nijmegen breakage syndrome 1 mutated gene 
NBS =  Nijmegen  breakage  syndrome 
IR =  Ionising  radiation 
BRCT  =  BRCA1 C-terminal domain 
NHL  =  Non Hodgkin lymphoma 
HL =  Hodgkin  lymphoma 
FISH  =  Fluorescence in situ hybridization 
OR =  Odds  ratio 
ATM  =  Ataxia telangiectasia mutated gene 
ALL =  Acute  lymphoblastic  leukaemia 
MRN =  MRE11/RAD50/NBS1  complex 
DSBs  =  Double strand breaks 
FHA  =  Forkhead associated domain 
ATR =  Ataxia  telangiectasia  related 
MDC1  =  Mediator of DNA damage checkpoint 
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